Curated News
By: NewsRamp Editorial Staff
March 11, 2026
BioStem Technologies to Host 2025 Financial Results Call on March 24
TLDR
- BioStem Technologies' upcoming financial results reveal investment opportunities in regenerative medicine, offering potential competitive advantages in the growing MedTech sector.
- BioStem Technologies will release Q4 and full year 2025 financial results on March 24, 2026, followed by a detailed conference call with CEO and CFO presentations.
- BioStem's focus on perinatal tissue allografts for regenerative therapies advances medical treatments that improve patient outcomes and quality of life.
- BioStem Technologies uses its proprietary BioRetain processing method to preserve growth factors in perinatal tissue for innovative regenerative medicine applications.
Impact - Why it Matters
This announcement matters because BioStem Technologies operates in the high-growth regenerative medicine sector, which is revolutionizing healthcare by offering advanced therapies for tissue repair and healing. Investors and stakeholders should care as the financial results will indicate the company's commercial traction and ability to scale its proprietary BioRetain® technology, potentially impacting stock performance and future funding for medical innovations. For patients, BioStem's progress could lead to more accessible regenerative treatments, addressing unmet needs in wound care and other conditions, while the broader MedTech industry watches for trends in perinatal tissue applications that could shape regulatory and market dynamics.
Summary
BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in regenerative medicine, has announced it will release its fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026. The company, which focuses on developing perinatal tissue allograft products, will host a conference call and webcast at 4:30 PM ET on that date, featuring CEO Jason Matuszewski and CFO Brandon Poe. This event provides investors and stakeholders with crucial insights into the company's financial performance and strategic direction, particularly as BioStem continues to innovate in the rapidly growing field of regenerative therapies.
The webcast will offer detailed information about the quarter's results, with registration available through a dedicated link. Key players include the executive leadership team, who will discuss the company's progress in manufacturing products that change lives using their proprietary BioRetain® processing method. This method preserves growth factors and tissue structure, aligning with current Good Tissue Practices and Good Manufacturing Processes accredited by the American Association of Tissue Banks. The company's portfolio includes brands like VENDAJE®, American Amnion™, Neox®, and Clarix®, which are central to its mission in regenerative medicine.
For more information, visit biostemtechnologies.com and follow the company on social media platforms such as X and LinkedIn. Investors can also sign up for the company's email distribution list to stay updated on developments. The news was distributed via PRISM MediaWire, a trusted press release distribution service, highlighting the importance of this announcement in the financial and medical technology sectors. This event underscores BioStem's commitment to transparency and engagement with its investor community as it advances its innovative therapies.
Source Statement
This curated news summary relied on content disributed by PRISM Mediawire. Read the original source here, BioStem Technologies to Host 2025 Financial Results Call on March 24
